Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
about
IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanomaPast, present and future of preserving and restoring function in the visual system: removing galectin-3 as a promising treatmentThe Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications.Hepatic stellate cells as key target in liver fibrosis.Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).Current and future pharmacological therapies for NAFLD/NASH.Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Preventing liver fibrosis in patients with NAFLD and the road ahead.Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.Galectin-3 Promotes Vascular Remodeling and Contributes to Pulmonary Hypertension.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.The Role of Galectins as Modulators of Metabolism and Inflammation.Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancerEmerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLDUtility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
P2860
Q33849567-E9DB38D5-0C00-4169-B4EF-DD3508E20F05Q38751747-8211411A-69FA-4048-8100-B1B40A6DC300Q39099711-74FE9FB7-C381-4CA7-91BD-FCE8DBCAB72AQ40200602-16A18911-50CA-4DFC-A951-42E3BC770DFCQ47329197-52F03D5A-6BEB-4C10-A6B2-C1AF5A27AD3AQ47778507-45AD96DC-AE6B-4D94-B853-32F8E726CDD6Q48159180-401A9BF3-D133-4461-A9B6-76A096CDD0A9Q48270428-62691EC0-FFC4-41AA-A1DB-0FC2CD638A69Q49363449-DEAA90B5-FE81-4D52-8375-E11F695DB4C9Q49790075-886DD465-0F7A-41D8-AC24-BEF12ADEF7CCQ49818334-00FECCC9-9789-4040-8CAC-889ED42A9465Q50136712-B885711D-BE54-468F-AD32-6C97EA33AA37Q55078604-F80A98F4-FBB8-49F1-8555-4D6E72269196Q55349770-D1AB100A-A15B-4552-9AB9-431DEF4ED5E5Q57807125-6E476BE3-333F-4426-8EFF-189A253FF631Q58716313-DDF541F0-7A49-4342-B8B2-343E77E77E3FQ58760217-02F5FDDB-4923-4C30-BC71-FA45FFDC9A5B
P2860
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@en
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@nl
type
label
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@en
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@nl
prefLabel
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@en
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@nl
P2093
P2860
P356
P1476
Randomised clinical study: GR- ...... atitis with advanced fibrosis.
@en
P2093
B A Neuschwander-Tetri
G A Thompson
M Noureddin
M Siddiqui
N Chalasani
P G Traber
S A Harrison
P2860
P304
P356
10.1111/APT.13816
P407
P50
P577
2016-10-24T00:00:00Z